Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 8/20 | 0.67 |
| ▸ | ADRB2 | P07550 | 7/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18016241 | 0.93 | CHRM3 (0.69) | CHRM3ADRB2DRD2DRD4CHRM4 | |
| SCHEMBL17978644 | 0.93 | CHRM3 (0.69) | CHRM3ADRB2DRD2DRD4CHRM4 | |
| Hydrochloric Acid SCHEMBL17978860 | 0.92 | CHRM3 (0.68) | CHRM3ADRB2DRD2DRD4CHRM4 | |
| Hydrochloric Acid SCHEMBL17978696 | 0.92 | CHRM3 (0.68) | CHRM3ADRB2DRD2DRD4CHRM4 | |
| SCHEMBL18812717 | 0.90 | CHRM3 (0.64) | CHRM3ADRB2CHRM4SLC6A5 | |
| SCHEMBL17985861 | 0.89 | CHRM3 (0.62) | CHRM3ADRB2DRD2DRD4CHRM4 | |
| SCHEMBL17985864 | 0.89 | CHRM3 (0.62) | CHRM3ADRB2DRD2DRD4CHRM4 | |
| SCHEMBL20307272 | 0.88 | CHRM3 (0.69) | CHRM3ADRB2DRD2DRD4 | |
| SCHEMBL18016243 | 0.88 | CHRM3 (0.69) | CHRM3ADRB2DRD2DRD4 | |
| Hydrochloric Acid SCHEMBL17979110 | 0.87 | CHRM3 (0.68) | CHRM3ADRB2DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9579314-B2 | Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-02-28 | — | — | US | disclosed |
| US-20160235734-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160235734-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | CHRM3 12/4885ADRB2 1/4885GAA 2937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.